[go: up one dir, main page]

WO2008140419A3 - Pyridyl substituted pyrimidine derivatives - Google Patents

Pyridyl substituted pyrimidine derivatives Download PDF

Info

Publication number
WO2008140419A3
WO2008140419A3 PCT/SG2008/000178 SG2008000178W WO2008140419A3 WO 2008140419 A3 WO2008140419 A3 WO 2008140419A3 SG 2008000178 W SG2008000178 W SG 2008000178W WO 2008140419 A3 WO2008140419 A3 WO 2008140419A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pyridyl substituted
substituted pyrimidine
disorders
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2008/000178
Other languages
French (fr)
Other versions
WO2008140419A2 (en
Inventor
Dizhong Chen
Cheng Hsia Angeline Lee
Harish Kumar Mysore Nagaraj
Anders Poulsen
Anthony Deodaunia William
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBio Pte Ltd
Original Assignee
SBio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBio Pte Ltd filed Critical SBio Pte Ltd
Publication of WO2008140419A2 publication Critical patent/WO2008140419A2/en
Publication of WO2008140419A3 publication Critical patent/WO2008140419A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to pyridyl substituted pyrimidine compounds that are useful as agents for the treatment of kinase related disorders such as proliferative disorders. More particularly, the present invention relates to oxygen linked and pyridyl substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of kinase related disorders such as proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.
PCT/SG2008/000178 2007-05-15 2008-05-14 Pyridyl substituted pyrimidine derivatives Ceased WO2008140419A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92444407P 2007-05-15 2007-05-15
US60/924,444 2007-05-15

Publications (2)

Publication Number Publication Date
WO2008140419A2 WO2008140419A2 (en) 2008-11-20
WO2008140419A3 true WO2008140419A3 (en) 2009-04-30

Family

ID=40002772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2008/000178 Ceased WO2008140419A2 (en) 2007-05-15 2008-05-14 Pyridyl substituted pyrimidine derivatives

Country Status (1)

Country Link
WO (1) WO2008140419A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8235986B2 (en) 2007-10-05 2012-08-07 Coaptus Medical Corporation Systems and methods for transeptal cardiac procedures, including tissue penetrating members and associated methods
CA3177164A1 (en) 2020-04-28 2021-11-04 Peter Sennhenn Bicyclic kinase inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
WO2008140419A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
PL1951729T3 (en) Oxygen linked pyrimidine derivatives
MY150993A (en) Pyrimidine substituted purine derivatives
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2012101654A3 (en) Novel triazine compounds
MX2009010047A (en) Chemical compounds.
MX2009010045A (en) Chemical compounds.
UA101611C2 (en) Compounds of imidazo[1,2-a]pyridine as receptor tyrosine kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008097640A3 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
ZA201000079B (en) Organic compounds
MX2009010037A (en) Aminopyrimidines useful as kinase inhibitors.
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2011082266A3 (en) Substituted heterocyclic compounds
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
MX2009011811A (en) Aminopyrimidines useful as kinase inhibitors.
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2010021918A8 (en) Compounds as kinase inhibitors
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2014016849A3 (en) Novel triazine compounds
MX336332B (en) Kinase inhibitors, prodrug forms thereof and their use in therapy.
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754016

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754016

Country of ref document: EP

Kind code of ref document: A2